GlassScriptPhysician profile
Kayla Spears
NPI 1114693108
$10,304.99
in general payments reported to CMS, 2019-2025
57 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $711 · 2022: $3,522 · 2023: $2,314 · 2024: $2,009 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,071.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,659.87 | 2021-2025 | |
| Novo Nordisk INC | $869.77 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Recordati_rare_diseases_inc. | $784.01 | 2022-2023 | Signifor Lar, Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $602.91 | 2021-2025 | |
| Corcept Therapeutics | $567.43 | 2021-2024 | Korlym |
| Amgen INC. | $505.92 | 2021-2025 | Otezla, Repatha, Repatha |
| Eusa Pharma (US) LLC | $458.52 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $374.63 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $374.15 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.73 | 2023-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $309.14 | 2022-2025 | |
| Antares Pharma, INC. | $263.53 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $241.16 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $191.35 | 2022-2025 | Rexulti |
| Ibsa Pharma INC. | $178.45 | 2021-2022 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $160.91 | 2022-2023 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $148.23 | 2022 | |
| Xeris Pharmaceuticals, INC. | $145.02 | 2022-2025 | Gvoke Hypopen |
| Dexcom, INC. | $142.52 | 2022-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $138.85 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $133.64 | 2023-2024 | Verquvo, Belsomra |
| Astellas Pharma US INC | $126.71 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $116.93 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $109.05 | 2025 | Fanapt |
| Mylan Specialty L.P. | $97.06 | 2023-2024 | Yupelri |
| Edwards Lifesciences Corporation | $87.86 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biohaven Pharmaceuticals, INC. | $79.27 | 2021 | |
| Almatica Pharma LLC | $78.14 | 2024-2025 | Loreev Xr |
| Corium, LLC | $74.07 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $68.27 | 2024-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $66.32 | 2021-2023 | |
| Lundbeck LLC | $65.72 | 2022-2024 | Rexulti, Vyepti |
| Nestle Healthcare Nutrition INC. | $61.13 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.94 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $51.84 | 2023-2024 | Xarelto, Spravato |
| Idorsia Pharmaceuticals US INC | $44.98 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $44.22 | 2021-2025 | Trintellix |
| Ardelyx, INC. | $42.97 | 2022-2023 | Ibsrela |
| Bausch Health US, LLC | $40.34 | 2022 | |
| Mannkind Corporation | $40.04 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $37.35 | 2025 | |
| Shield Therapeutics INC | $32.01 | 2024 | |
| Azurity Pharmaceuticals, INC. | $31.46 | 2023 | Adthyza |
| Grt US Holding, INC. | $31.18 | 2022 | |
| Averitas Pharma INC. | $24.59 | 2023 | Qutenza |
| Exact Sciences Corporation | $21.56 | 2025 | Cologuard Collection Kit |
| Alkermes, INC. | $20.36 | 2022 | |
| Viatris Specialty LLC | $19.44 | 2025 | Yupelri |
| Halozyme INC | $19.26 | 2023 | |
| Sumitomo Pharma America, INC. | $18.38 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $17.97 | 2022 | |
| Insulet Corporation | $16.22 | 2021 | |
| Neurocrine Biosciences, INC. | $15.64 | 2025 | |
| Ironwood Pharmaceuticals, INC | $15.51 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.92 | 2023 | Unithroid |
| Exeltis, USA INC. | $13.20 | 2022 | |
| Organon LLC | $12.34 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.